Downregulation of TAP2 and to a lesser extent, TAP1, have been found to increase immune evasion in tumors. Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, discusses the clinical implications and future research potential for these findings. Elucidating additional mutations in TAP1/2, novel molecular targets such as RBBP7 and epigenetic modulators are crucial to exploit TAP1/2 downregulation to increase PD-L1 inhibitor efficacy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
